{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T06:32:07Z","timestamp":1795242727075,"version":"4.10.3"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ygyno.2026.01.777","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:38:55Z","timestamp":1770971935000},"page":"54-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Biomarker heterogeneity and efficacy of durvalumab plus carboplatin\/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E\/GOG-3041\/ENGOT-EN10 trial"],"prefix":"10.1016","volume":"206","author":[{"given":"Shannon N.","family":"Westin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Sook","family":"Chon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Thomes","family":"Pepin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin A.","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Starks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Disilvestro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Slomovitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elen","family":"Vettus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"G\u00e1lvez-Montosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kofi","family":"Agyemang-Prempeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Weon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Contreras","family":"Mejia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreia Cristina","family":"De Melo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadaaki","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Kowgier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Van Nieuwenhuysen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2022","key":"10.1016\/j.ygyno.2026.01.777_bb0005","first-page":"7","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0010","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.annonc.2022.05.009","article-title":"Endometrial cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Oaknin","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ygyno.2026.01.777_bb0020","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0025","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40661-016-0035-4","article-title":"New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care","volume":"3","author":"Talhouk","year":"2016","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0030","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1200\/JCO.20.00549","article-title":"Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy","volume":"38","author":"Le\u00f3n-Castillo","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0035","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2015.190","article-title":"A clinically applicable molecular-based classification for endometrial cancers","volume":"113","author":"Talhouk","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.01.777_bb0040","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1016\/S1470-2045(25)00167-6","article-title":"ESGO-ESTRO-ESP guidelines for the management of patients with endometrial carcinoma: update 2025","volume":"26","author":"Concin","year":"2025","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0045","doi-asserted-by":"crossref","first-page":"S730","DOI":"10.1016\/j.annonc.2021.08.1237","article-title":"795MO pembrolizumab (pembro) in patients (pts) with microsatellite instability-high (MSI-H) advanced endometrial cancer (EC): updated results from KEYNOTE-158","volume":"32","author":"O'Malley","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0050","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jamaoncol.2020.4515","article-title":"Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial","volume":"6","author":"Oaknin","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0060","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1056\/NEJMoa2216334","article-title":"Dostarlimab for primary advanced or recurrent endometrial cancer","volume":"388","author":"Mirza","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0065","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa2302312","article-title":"Pembrolizumab plus chemotherapy in advanced endometrial cancer","volume":"388","author":"Eskander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0070","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1200\/JCO.23.02132","article-title":"Durvalumab plus carboplatin\/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial","volume":"42","author":"Westin","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0075","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/S1470-2045(24)00334-6","article-title":"Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"25","author":"Colombo","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0085","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ijgo.14969","article-title":"Molecular subtypes of endometrial cancer: implications for adjuvant treatment strategies","volume":"164","author":"Yang","year":"2024","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0090","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13045-019-0784-8","article-title":"Prospects for combining immune checkpoint blockade with PARP inhibition","volume":"12","author":"Li","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0095","doi-asserted-by":"crossref","first-page":"6717","DOI":"10.1158\/0008-5472.CAN-18-2652","article-title":"Development of PARP and immune-checkpoint inhibitor combinations","volume":"78","author":"Stewart","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.816642","article-title":"Targeting PARP1 to enhance anticancer checkpoint immunotherapy response: rationale and clinical implications","volume":"13","author":"Wanderley","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0110","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.annonc.2021.11.013","article-title":"European experts consensus: BRCA\/homologous recombination deficiency testing in first-line ovarian cancer","volume":"33","author":"Vergote","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0115","series-title":"Global Policy: Bioethics","author":"AstraZeneca.","year":"2025"},{"key":"10.1016\/j.ygyno.2026.01.777_bb0120","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13000-023-01318-8","article-title":"Tumor area positivity (TAP) score of programmed death-ligand 1 (PD-L1): a novel visual estimation method for combined tumor cell and immune cell scoring","volume":"18","author":"Liu","year":"2023","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0125","doi-asserted-by":"crossref","first-page":"A118","DOI":"10.1136\/ijgc-2022-ESGO.257","article-title":"2022-RA-922-ESGO\u00a0Histo-molecular characteristics of platinum-sensitive advanced endometrial cancer: data issued from the population included in the GINECO UTOLA study","volume":"32","author":"Joly","year":"2022","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2026.01.777_bb0130","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.annonc.2024.04.007","article-title":"MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy","volume":"35","author":"Pignata","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0135","doi-asserted-by":"crossref","first-page":"S507","DOI":"10.1016\/j.annonc.2023.09.1919","volume":"34","author":"Mirza","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0140","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jamaoncol.2022.2181","article-title":"Evaluation of treatment with talazoparib and avelumab in patients with recurrent mismatch repair proficient endometrial cancer","volume":"8","author":"Konstantinopoulos","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0145","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0150","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1038\/s41591-025-03566-1","article-title":"Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial","volume":"31","author":"Eskander","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0155","doi-asserted-by":"crossref","first-page":"4564","DOI":"10.1158\/1078-0432.CCR-22-3915","article-title":"Safety, efficacy, and biomarker analyses of dostarlimab in patients with endometrial cancer: interim results of the phase I GARNET study","volume":"29","author":"Oaknin","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0160","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.3390\/jcm11113114","article-title":"Endometrial cancer and BRCA mutations: a systematic review","volume":"11","author":"Gasparri","year":"2022","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.gocm.2020.10.006","article-title":"BRCA1\/2 mutations and survival of high-grade endometrioid endometrial cancer","volume":"1","author":"Dai","year":"2021","journal-title":"Gynecol. Obstet. Clin. Med."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0170","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-18-1443","article-title":"Frequent homologous recombination deficiency in high-grade endometrial carcinomas","volume":"25","author":"de Jonge","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0175","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2025.36.e62","article-title":"Mutations in homologous recombination repair genes in patients with metastatic endometrial cancer: association with clinical characteristics and prognosis","volume":"36","author":"Zhong","year":"2025","journal-title":"J. Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0180","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/his.12053","article-title":"Molecular pathology of endometrial carcinoma","volume":"62","author":"Matias-Guiu","year":"2013","journal-title":"Histopathology"},{"key":"10.1016\/j.ygyno.2026.01.777_bb0185","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/PGP.0000000000000243","article-title":"TP53 mutational spectrum in endometrioid and serous endometrial cancers","volume":"35","author":"Schultheis","year":"2016","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0190","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.ygyno.2024.07.015","article-title":"Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin\/paclitaxel as compared to carboplatin\/paclitaxel plus placebo in the NRG GY018 trial","volume":"190","author":"Eskander","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2026.01.777_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103538","article-title":"38MO progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA\/rEC) in the overall and mismatch repair proficient (MMR\/MSS) populations and in histological and molecular subgroups: results from part 2 of the RUBY trial","volume":"9","author":"Mirza","year":"2024","journal-title":"ESMO Open"},{"issue":"Suppl. 5","key":"10.1016\/j.ygyno.2026.01.777_bb0200","article-title":"37MO Dostarlimab plus chemotherapy in primary advanced or recurrent endometrial cancer (pA\/rEC) in the RUBY trial: overall survival (OS) by MMR status and molecular subgroups","volume":"9","author":"Powell","year":"2024","journal-title":"ESMO Open"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826007791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826007791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T17:22:03Z","timestamp":1782926523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826007791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":39,"alternative-id":["S0090825826007791"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.01.777","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarker heterogeneity and efficacy of durvalumab plus carboplatin\/paclitaxel followed by durvalumab with or without olaparib in patients with mismatch repair proficient endometrial cancer: exploratory analyses of the DUO-E\/GOG-3041\/ENGOT-EN10 trial","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.01.777","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}